Edwards Lifesciences Q2 2024 Adj EPS $0.70 Beats $0.69 Estimate, Sales $1.632B Miss $1.653B Estimate
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences (NYSE:EW) reported Q2 2024 adjusted EPS of $0.70, beating the estimate of $0.69. However, sales of $1.632 billion missed the estimate of $1.653 billion. Sales increased by 6.67% year-over-year.
July 24, 2024 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Edwards Lifesciences reported Q2 2024 EPS of $0.70, beating estimates, but sales of $1.632 billion missed expectations. Sales increased by 6.67% year-over-year.
The mixed results, with EPS beating but sales missing estimates, may lead to a neutral short-term impact on the stock price. The year-over-year sales growth of 6.67% is a positive sign, but the sales miss could offset this.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100